Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5579021 | 0.97 | SIGMAR1 (0.50) | SIGMAR1NOTUMOPRL1OPRM1OPRK1 | |
| SCHEMBL5579084 | 0.85 | OPRM1 (0.48) | SIGMAR1OPRL1OPRM1OPRK1KCNH2 | |
| SCHEMBL5578940 | 0.84 | SIGMAR1 (0.49) | SIGMAR1NOTUMOPRL1HDAC1HDAC6 | |
| SCHEMBL14580774 | 0.84 | OPRL1 (0.54) | SIGMAR1NOTUMOPRL1OPRM1OPRK1 | |
| SCHEMBL5578522 | 0.84 | SIGMAR1 (0.51) | SIGMAR1NOTUMOPRM1HDAC1HDAC6 | |
| SCHEMBL5578527 | 0.84 | NOTUM (0.50) | SIGMAR1NOTUMHDAC1HDAC6 | |
| SCHEMBL14580848 | 0.83 | OPRL1 (0.56) | SIGMAR1NOTUMOPRL1OPRM1OPRK1 | |
| SCHEMBL5578762 | 0.83 | OPRM1 (0.50) | SIGMAR1OPRL1OPRM1OPRK1 | |
| SCHEMBL5578609 | 0.82 | OPRM1 (0.52) | SIGMAR1OPRL1OPRM1OPRK1 | |
| SCHEMBL5578501 | 0.81 | NOTUM (0.50) | SIGMAR1NOTUMHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | SIGMAR1 444/4885NOTUM 3318/4885OPRL1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.